Pathogenesis and Treatment of Pancreatic Cancer Related Pain

LOHSE, INES; BROTHERS, SHAUN P.

doi:10.21873/anticanres.14133

Cited by 49 publications

(44 citation statements)

References 94 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Such agents must therefore be identified, minimized, or possibly discontinued. Opioid rotation should be considered in patients with inadequate pain relief despite repeated dose escalations, in the presence of OIN, or when side effects preclude dose escalation, using equianalgesic opioid ratios with appropriate initiating dose reductions of 50%–75% to compensate for incomplete cross‐tolerance [47, 57].…”

Section: Opioidsmentioning

confidence: 99%

Pancreas Cancer-Associated Pain Management

et al. 2021

View full text Add to dashboard Cite

Pain is highly prevalent in patients with pancreas cancer and contributes to the morbidity of the disease. Pain may be due to pancreatic enzyme insufficiency, obstruction, and/or a direct mass effect on nerves in the celiac plexus. Proper supportive care to decrease pain is an important aspect of the overall management of these patients. There are limited data specific to the management of pain caused by pancreatic cancer. Here we review the literature and offer recommendations regarding multiple modalities available to treat pain in these patients. The dissemination and adoption of these best supportive care practices can improve quantity and quality of life for patients with pancreatic cancer. Implications for Practice Pain management is important to improve the quality of life and survival of a patient with cancer. The pathophysiology of pain in pancreas cancer is complex and multifactorial. Despite tumor response to chemotherapy, a sizeable percentage of patients are at risk for ongoing cancer‐related pain and its comorbid consequences. Accordingly, the management of pain in patients with pancreas cancer can be challenging and often requires a multifaceted approach.

show abstract

Section: Opioidsmentioning

confidence: 99%

Pancreas Cancer-Associated Pain Management

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Obesity has been linked to a proinflammatory state that causes nociceptive hypersensitivity with a heightened perception of pain [19,20] and psychological distress [21,22]. Betcher et al have correlated a higher BMI, lower level of education, greater neuroticism, and less social support with self-controlled behavior and greater anguish [22].…”

Section: Introductionmentioning

confidence: 99%

Impact of Obesity on Quality of Life, Psychological Distress, and Coping on Patients with Colon Cancer

et al. 2021

View full text Add to dashboard Cite

Background. Despite the causal relationship between obesity and colon cancer being firmly established the effect of obesity on the course of cancer calls for further elucidation. The objective was to assess differences in clinicalpathological and psychosocial variables between obese and non-obese individuals with colon cancer. Patients and Methods. Prospective, multicentric, observational study conducted from 2015-2018. The sample comprised patients with stage II-III, resected colon cancer about to initiate adjuvant chemotherapy with fluoropyrimidine in monotherapy or associated with oxaliplatin and grouped into non-obese (BMI <30kg/m 2) or obese (≥30kg/m 2). Subjects completed questionnaires appraising quality of life (EORTC-QLQ-C30), coping (M-MAC), psychological distress (BSI-18), perceived social support (MSPSS), personality (BFI-10), and pain (BPI). Toxicity, chemotherapy compliance, 12-month recurrence and mortality rate data were recorded. Results. Seventy-nine of the 402 individuals recruited (19.7%) were obese. Obese subjects exhibited more comorbidities (≥2 comorbidities, 46.8% vs 30.3%, p=0.001) and expressed feeling slightly more postoperative pain (small size-effect). There was more depression, greater helplessness, less perceived social support from friends, and greater extraversion among the obese versus non-obese subjects (all p<0.04). The non-obese group treated with fluoropyrimidine and oxaliplatin suffered more grade 3-4 hematological toxicity (p=0.035), whereas the obese had higher rates of treatment withdrawal (17.7% vs 7.7%, p=0.033) and more recurrences (10.1% vs 3.7%, p=0.025). No differences in sociodemographic, quality of life, or 12-month survival variables were detected. Conclusion. Obesity appears to affect how people confront cancer, as well as their tolerance to oncological treatment and relapse. The Oncologist 2021;9999:• • Implications for Practice: Obesity is a causal factor and affects prognosis in colorectal cancer. Obese patients displayed more comorbidities, more pain following cancer surgery, worse coping, more depression, and perceived less social support than the non-obese. Severe hematological toxicity was more frequent among non-obese

show abstract

“…Genistein, a poly-phenolic compounds found in soya seeds (Glycine soja), in conjunction with cisplatin, increased the production of pancreatic cancer cell line BXPC-3 and stimulated their apoptosis and consequent decrease of tumor growth shown in vivo [30,31]. Besides to all this, after the administration of intraperitoneal cisplatin supplements, Genistein and 5-fluorouracil, the regression of cancer in the C 57 B16 rats with the Lewis lung carcinoma cells was observed [32].…”

Section: Genisteinmentioning

confidence: 99%

Synergistic Anti-Cancer Effects of Natural Products and Their Mode of Action

Gupta

2021

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Cancer has emerged as the second leading cause of death globally. There has been a lot of interest in other treatments like this. This includes hormonal supplements, radiation therapy, chemotherapy, surgery, and other medicines which are used in singles or combinations. Therefore, due to the habit of patient combination therapy, interactions of other drugs like hormonal supplements may be of great risk. Without consulting the doctor, the administration of herbal medicines by patients is growing rapidly in the whole world. There is also a possibility of herbal medicines. Extracts or herbal medicines are a combination of active ingredients that automatically interacts with other medicines to increase or reduce the therapeutic effect. This review focuses on the interactions of herbal medicines as well as on different types of nanoparticles (NPs), which are affected by various types of cancer treatment. Dietetic phytochemicals such as genestin, curcumin, epiglottits gillette, quercetin, and resveratrol have been given special emphasis on their working mechanism. All phytochemicals increase their therapeutic effects either by increasing the bio-availability of other drugs or by stabilizing some other medicines in the system.

show abstract

Pathogenesis and Treatment of Pancreatic Cancer Related Pain

Abstract: Pancreatic cancer patients typically suffer from high levels of abdominal pain symptoms that arise from a variety of causes including tissue damage, inflammation, ductal obstruction and infiltration, and can be visceral, somatic or neuropathic in origin (28-33).

Cited by 49 publications

References 94 publications

Pancreas Cancer-Associated Pain Management

Pancreas Cancer-Associated Pain Management

Impact of Obesity on Quality of Life, Psychological Distress, and Coping on Patients with Colon Cancer

Synergistic Anti-Cancer Effects of Natural Products and Their Mode of Action

Contact Info

Product

Resources

About